Glucoregulatory impairment has reached epidemic proportions in the United States. According to the American Diabetes Association,
1 29.1 million individuals in the United States have diabetes mellitus, and more than half of adults older than 64 years have prediabetes. Type 2 diabetes mellitus increases the risk for Alzheimer disease (AD), and clinical and preclinical hypergylcemia are characterized by insulin resistance.
Insulin resistance is broadly defined as reduced tissue responsiveness to the action of insulin.
2 Insulin, a key hormone involved in carbohydrate metabolism, facilitates microvascular blood flow, glucose uptake, and glucose oxidation for adenosine-5′-triphosphate generation.
3